Clinical Pearls from the 2025 Fall Clinical PA/NP Meeting: Day 3
FDA Approves Dupilumab, First and Only Targeted Medicine for Bullous Pemphigoid
Q&A Part 1: Reviewing the Significance of Lebrikizumab for Patients With Skin of Color, With Anabela Cardoso, MD
Daily Derm Times: June 19, 2025